Alectinib Hydrochloride

CHEMBL3707320 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

519.1 g/mol

LogP

—

Phase

4

The hydrochloride salt formulation of alectinib, an ALK tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This salt form improves the drug's solubility and oral absorption while delivering the same targeted blockade of abnormal ALK signaling that drives cancer cell growth.

Masse moléculaire

519,1000 g/mol

TPSA

72,40 Å²

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

Mécanisme d'action

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl

InChI

InChI=1S/C30H34N4O2.ClH/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29;/h5-6,15-17,21,32H,4,7-14H2,1-3H3;1H

Molecular Formula

C30H35ClN4O2

HBD / HBA

2 / 5

Liaisons Rotatives

3

Atomes Lourds

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The hydrochloride salt formulation of alectinib, an ALK tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This salt form improves the drug's solubility and oral absorption while delivering the same targeted blockade of abnormal ALK signaling that drives cancer cell growth.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Alectinib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707320. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 53239799. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Alectinib Hydrochloride sur PillFYI

Structure

Données Clés

Formule: C30H35ClN4O2
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.